Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Apr;38(4):750–756. doi: 10.1128/aac.38.4.750

Ceftriaxone protects against tobramycin nephrotoxicity.

D Beauchamp 1, G Thériault 1, L Grenier 1, P Gourde 1, S Perron 1, Y Bergeron 1, L Fontaine 1, M G Bergeron 1
PMCID: PMC284537  PMID: 8031041

Abstract

The effect of ceftriaxone on tobramycin-induced nephrotoxicity was investigated. Female Sprague-Dawley rats were treated during 4 and 10 days with saline (NaCl, 0.9%), ceftriaxone at a dose of 100 mg/kg of body weight/12 h subcutaneously, tobramycin at doses of 40 and 60 mg/kg/12 h intraperitoneally, or the combination ceftriaxone-tobramycin. Creatinine levels in serum were significantly higher in animals treated with tobramycin alone given at 60 mg/kg/12 h during 10 days, compared with control animals (P < 0.01) or animals receiving the combination tobramycin-ceftriaxone (P < 0.01). After 10 days of treatment, ceftriaxone did not accumulate in renal tissue but did reduce the renal intracortical accumulation of tobramycin (P < 0.05). Tobramycin given alone at either 40 or 60 mg/kg/12 h induced a significant inhibition of sphingomyelinase activity compared with control animals (P < 0.05). However, this enzyme activity was significantly less inhibited when tobramycin was injected in combination with ceftriaxone (P < 0.05). Ceftriaxone alone had no effect on the activity of this enzyme. The [3H]thymidine incorporation into the DNA of renal cortex was also significantly lower in animals treated with tobramycin-ceftriaxone compared with animals receiving tobramycin alone (P < 0.05). The 24-h urinary excretion of beta-galactosidase was significantly reduced in animals treated with the combination tobramycin-ceftriaxone compared with the administration of tobramycin alone at 40 and 60 mg/kg/12 h after 5 and 10 days (P < 0.05). Histologically, ceftriazone induced very few cellular alterations and reduced considerably the presence of typical signs of tobramycin nephrotoxicity. This investigation demonstrated that ceftriaxone protects animals against tobramycin-induced nephrotoxicity.

Full text

PDF
750

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angehrn P. In vitro and in vivo synergy between ceftriaxone and aminoglycosides against Pseudomonas aeruginosa. Eur J Clin Microbiol. 1983 Oct;2(5):489–495. doi: 10.1007/BF02013914. [DOI] [PubMed] [Google Scholar]
  2. Beam T. R., Jr Ceftriaxone: a beta-lactamase-stable, broad-spectrum cephalosporin with an extended half-life. Pharmacotherapy. 1985 Sep-Oct;5(5):237–253. doi: 10.1002/j.1875-9114.1985.tb03423.x. [DOI] [PubMed] [Google Scholar]
  3. Beauchamp D., Gourde P., Bergeron M. G. Subcellular distribution of gentamicin in proximal tubular cells, determined by immunogold labeling. Antimicrob Agents Chemother. 1991 Nov;35(11):2173–2179. doi: 10.1128/aac.35.11.2173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Beauchamp D., Laurent G., Maldague P., Abid S., Kishore B. K., Tulkens P. M. Protection against gentamicin-induced early renal alterations (phospholipidosis and increased DNA synthesis) by coadministration of poly-L-aspartic acid. J Pharmacol Exp Ther. 1990 Nov;255(2):858–866. [PubMed] [Google Scholar]
  5. Beauchamp D., Laurent G., Maldague P., Tulkens P. M. Reduction of gentamicin nephrotoxicity by the concomitant administration of poly-l-aspartic acid and poly-l-asparagine in rats. Arch Toxicol Suppl. 1986;9:306–309. doi: 10.1007/978-3-642-71248-7_52. [DOI] [PubMed] [Google Scholar]
  6. Beauchamp D., Pellerin M., Gourde P., Pettigrew M., Bergeron M. G. Effects of daptomycin and vancomycin on tobramycin nephrotoxicity in rats. Antimicrob Agents Chemother. 1990 Jan;34(1):139–147. doi: 10.1128/aac.34.1.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Beauchamp D., Pettigrew M. Influence of hydrocortisone on gentamicin-induced nephrotoxicity in rats. Antimicrob Agents Chemother. 1988 Jul;32(7):992–996. doi: 10.1128/aac.32.7.992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bennett W. M., Elliott W. C., Houghton D. C., Gilbert D. N., DeFehr J., McCarron D. A. Reduction of experimental gentamicin nephrotoxicity in rats by dietary calcium loading. Antimicrob Agents Chemother. 1982 Sep;22(3):508–512. doi: 10.1128/aac.22.3.508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Blanc C., Pollet J. P., Bauters F. Ceftriaxone plus amikacin in neutropenic patients: a report on 100 cases. Chemotherapy. 1991;37(5):382–388. doi: 10.1159/000238883. [DOI] [PubMed] [Google Scholar]
  10. Bloch R., Luft F. C., Rankin L. I., Sloan R. S., Yum M. N., Maxwell D. R. Protection from gentamicin nephrotoxicity by cephalothin and carbenicillin. Antimicrob Agents Chemother. 1979 Jan;15(1):46–49. doi: 10.1128/aac.15.1.46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Branch R. A., Jackson E. K., Jacqz E., Stein R., Ray W. A., Ohnhaus E. E., Meusers P., Heidemann H. Amphotericin-B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline. Klin Wochenschr. 1987 Jun 1;65(11):500–506. doi: 10.1007/BF01721035. [DOI] [PubMed] [Google Scholar]
  12. Branch R. A. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med. 1988 Nov;148(11):2389–2394. [PubMed] [Google Scholar]
  13. Chow M. S., Quintiliani R., Nightingale C. H. In vivo inactivation of tobramycin by ticarcillin. A case report. JAMA. 1982 Feb 5;247(5):658–659. [PubMed] [Google Scholar]
  14. Dellinger P., Murphy T., Pinn V., Barza M., Weinstein L. Protective effect of cephalothin against gentamincin-induced nephrotoxicity in rats. Antimicrob Agents Chemother. 1976 Jan;9(1):172–178. doi: 10.1128/aac.9.1.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ebert S. C., Jorgensen J. H., Drutz D. J., Clementi W. A. Comparative assessment of in vitro inactivation of gentamicin in the presence of carbenicillin by three different gentamicin assay methods. J Clin Microbiol. 1984 Oct;20(4):701–705. doi: 10.1128/jcm.20.4.701-705.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Engineer M. S., Bodey G. P., Sr, Newman R. A., Ho D. H. Effects of cisplatin-induced nephrotoxicity on gentamicin pharmacokinetics in rats. Drug Metab Dispos. 1987 May-Jun;15(3):329–334. [PubMed] [Google Scholar]
  17. English J., Gilbert D. N., Kohlhepp S., Kohnen P. W., Mayor G., Houghton D. C., Bennett W. M. Attenuation of experimental tobramycin nephrotoxicity by ticarcillin. Antimicrob Agents Chemother. 1985 Jun;27(6):897–902. doi: 10.1128/aac.27.6.897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Fantin B., Pangon B., Potel G., Vallois J. M., Caron F., Bure A., Carbon C. Ceftriaxone-netilmicin combination in single-daily-dose treatment of experimental Escherichia coli endocarditis. Antimicrob Agents Chemother. 1989 May;33(5):767–770. doi: 10.1128/aac.33.5.767. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Fekety F. R. Safety of parenteral third-generation cephalosporins. Am J Med. 1990 Apr 9;88(4A):38S–44S. doi: 10.1016/0002-9343(90)90326-9. [DOI] [PubMed] [Google Scholar]
  20. Francioli P. B., Glauser M. P. Synergistic activity of ceftriaxone combined with netilmicin administered once daily for treatment of experimental streptococcal endocarditis. Antimicrob Agents Chemother. 1993 Feb;37(2):207–212. doi: 10.1128/aac.37.2.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Furuhama K., Onodera T. The influence of cephem antibiotics on gentamicin nephrotoxicity in normal, acidotic, dehydrated, and unilaterally nephrectomized rats. Toxicol Appl Pharmacol. 1986 Dec;86(3):430–436. doi: 10.1016/0041-008x(86)90370-4. [DOI] [PubMed] [Google Scholar]
  22. Gilbert D. N., Wood C. A., Kohlhepp S. J., Kohnen P. W., Houghton D. C., Finkbeiner H. C., Lindsley J., Bennett W. M. Polyaspartic acid prevents experimental aminoglycoside nephrotoxicity. J Infect Dis. 1989 May;159(5):945–953. doi: 10.1093/infdis/159.5.945. [DOI] [PubMed] [Google Scholar]
  23. Giurgea-Marion L., Toubeau G., Laurent G., Heuson-Stiennon J. A., Tulkens P. M. Impairment of lysosome-pinocytic vesicle fusion in rat kidney proximal tubules after treatment with gentamicin at low doses. Toxicol Appl Pharmacol. 1986 Nov;86(2):271–285. doi: 10.1016/0041-008x(86)90058-x. [DOI] [PubMed] [Google Scholar]
  24. Hoepelman I. M., Rozenberg-Arska M., Verhoef J. Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for treatment of serious bacterial infections. Lancet. 1988 Jun 11;1(8598):1305–1309. doi: 10.1016/s0140-6736(88)92121-6. [DOI] [PubMed] [Google Scholar]
  25. Inouye S., Niizato T., Takeda U., Koeda T. Protective effect of fosfomycin on the experimental nephrotoxicity induced by dibekacin. J Pharmacobiodyn. 1982 Sep;5(9):659–669. doi: 10.1248/bpb1978.5.659. [DOI] [PubMed] [Google Scholar]
  26. Kojima R., Ito M., Suzuki Y. Studies on the nephrotoxicity of aminoglycoside antibiotics and protection from these effects (3). Protective effect of latamoxef against tobramycin nephrotoxicity and its protective mechanism. Jpn J Pharmacol. 1986 Nov;42(3):397–404. doi: 10.1254/jjp.42.397. [DOI] [PubMed] [Google Scholar]
  27. Kojima R., Ito M., Suzuki Y. Studies on the nephrotoxicity of aminoglycoside antibiotics and protection from these effects (7): Effect of latamoxef on binding of tobramycin to brush border membranes isolated from rat kidney cortex. Jpn J Pharmacol. 1989 Dec;51(4):465–473. doi: 10.1254/jjp.51.465. [DOI] [PubMed] [Google Scholar]
  28. Krcméry V., Jr, Koza I., Mardiak J., Fuchsberger P., Spánik S., Trupl J., Horníková M., Kusenda Z., Sufliarsky J., Svec J. Netilmicin plus ceftriaxone versus amikacin plus ceftriaxone in the treatment of infections in granulocytopenic patients. Chemotherapy. 1992;38(1):74–76. doi: 10.1159/000238944. [DOI] [PubMed] [Google Scholar]
  29. Laurent G., Carlier M. B., Rollman B., Van Hoof F., Tulkens P. Mechanism of aminoglycoside-induced lysosomal phospholipidosis: in vitro and in vivo studies with gentamicin and amikacin. Biochem Pharmacol. 1982 Dec 1;31(23):3861–3870. doi: 10.1016/0006-2952(82)90303-3. [DOI] [PubMed] [Google Scholar]
  30. Laurent G., Maldague P., Carlier M. B., Tulkens P. M. Increased renal DNA synthesis in vivo after administration of low doses of gentamicin to rats. Antimicrob Agents Chemother. 1983 Oct;24(4):586–593. doi: 10.1128/aac.24.4.586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Luft F. C., Patel V., Yum M. N., Kleit S. A. Nephrotoxicity of cephalosporin-gentamicin combinations in rats. Antimicrob Agents Chemother. 1976 May;9(5):831–839. doi: 10.1128/aac.9.5.831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Luft F. C., Rankin L. I., Sloan R. S., Yum M. N. Recovery from aminoglycoside nephrotoxicity with continued drug administration. Antimicrob Agents Chemother. 1978 Sep;14(3):284–287. doi: 10.1128/aac.14.3.284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Martino P., Girmenia C., Raccah R., Micozzi A., Cimino G., Sgadari C., Gentile G. Single daily dose ceftriaxone plus amikacin treatment of febrile episodes in neutropenic patients attending day hospital for hematologic malignancies. Oncology. 1992;49(1):49–52. doi: 10.1159/000227010. [DOI] [PubMed] [Google Scholar]
  34. Maruhn D. Rapid colorimetric assay of beta-galactosidase and N-acetyl-beta-glucosaminidase in human urine. Clin Chim Acta. 1976 Dec;73(3):453–461. doi: 10.1016/0009-8981(76)90147-9. [DOI] [PubMed] [Google Scholar]
  35. Ngeleka M., Beauchamp D., Tardif D., Auclair P., Gourde P., Bergeron M. G. Endotoxin increases the nephrotoxic potential of gentamicin and vancomycin plus gentamicin. J Infect Dis. 1990 Apr;161(4):721–727. doi: 10.1093/infdis/161.4.721. [DOI] [PubMed] [Google Scholar]
  36. Ohnishi A., Bryant T. D., Branch K. R., Sabra R., Branch R. A. Role of sodium in the protective effect of ticarcillin on gentamicin nephrotoxicity in rats. Antimicrob Agents Chemother. 1989 Jun;33(6):928–932. doi: 10.1128/aac.33.6.928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Richards D. M., Heel R. C., Brogden R. N., Speight T. M., Avery G. S. Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1984 Jun;27(6):469–527. doi: 10.2165/00003495-198427060-00001. [DOI] [PubMed] [Google Scholar]
  38. Silverblatt F. J., Kuehn C. Autoradiography of gentamicin uptake by the rat proximal tubule cell. Kidney Int. 1979 Apr;15(4):335–345. doi: 10.1038/ki.1979.45. [DOI] [PubMed] [Google Scholar]
  39. Thiel G., McDonald F. D., Oken D. E. Micropuncture studies of the basis for protection of renin depleted rats from glycerol induced acute renal failure. Nephron. 1970;7(1):67–79. doi: 10.1159/000179809. [DOI] [PubMed] [Google Scholar]
  40. Watanakunakorn C. In vitro activity of ceftriaxone alone and in combination with gentamicin, tobramycin, and amikacin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1983 Aug;24(2):305–306. doi: 10.1128/aac.24.2.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Williams P. D., Hottendorf G. H., Bennett D. B. Inhibition of renal membrane binding and nephrotoxicity of aminoglycosides. J Pharmacol Exp Ther. 1986 Jun;237(3):919–925. [PubMed] [Google Scholar]
  42. Wood C. A., Finkbeiner H. C., Kohlhepp S. J., Kohnen P. W., Gilbert D. N. Influence of daptomycin on staphylococcal abscesses and experimental tobramycin nephrotoxicity. Antimicrob Agents Chemother. 1989 Aug;33(8):1280–1285. doi: 10.1128/aac.33.8.1280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Wood C. A., Kohlhepp S. J., Kohnen P. W., Houghton D. C., Gilbert D. N. Vancomycin enhancement of experimental tobramycin nephrotoxicity. Antimicrob Agents Chemother. 1986 Jul;30(1):20–24. doi: 10.1128/aac.30.1.20. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES